-
-
-
-
-
-
-
Aurinia Pharmaceuticals stock surges 4% on plans to pursue a possible sale
-
-
-
-
-
-
-
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aurinia, Stronghold, Lilium, and Li-Cycle and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Aurinia Pharmaceuticals (AUPH) Acquires Novel Pipeline Targeting Autoimmune and Kidney-related Diseases
-
-
-
-
-
-
-
Pre-Open Movers 04/11: (SALE) (TNXP) (MXWL) Higher; (CYTX) (AFSI) (SLP) Lower (more...)
-
-
-
-
-
-
-
Pre-Open Stock Moves 11/03: (IQNT) (LSCC) (AUPH) Higher; (DPLO) (FIT) (FB) Lower (more...)
-
-
-
-
-
-
-
Aurinia Pharmaceuticals (AUPH) Names Charles Rowland CEO
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

